Treating Microvascular Angina: What Actually Helps

Microvascular angina is treatable, but only once you know which kind you have. The most common reason women with this condition cycle through three or four medications without relief is not that the drugs do not work; it is that the drug was chosen without knowing the mechanism it needed to target.

The Mechanism

Coronary microvascular dysfunction (CMD) is not a single physiological failure. The term describes at least two distinct functional abnormalities of the small coronary vessels, vessels that fall below the resolution of standard coronary angiography and are therefore invisible on the catheterization images that come back labeled “normal.” These abnormalities can occur independently or simultaneously, and they require different treatments. Treating across them empirically, without knowing which one is dominant, is how therapy fails.

Impaired microvascular vasodilation describes a state in which the coronary microvasculature cannot increase blood flow appropriately in response to increased myocardial demand. Under normal conditions, the microvessels dilate to meet demand through endothelium-dependent and endothelium-independent mechanisms: nitric oxide released from endothelial cells relaxes vascular smooth muscle, and adenosine produced during metabolic activity serves as a direct vasodilator. When the endothelium is dysfunctional or the microvasculature is structurally abnormal from longstanding hypertension, diabetes, or other insults, this dilation is blunted. The result is ischemia with exertion even though the large vessels appear unobstructed. Coronary flow reserve (CFR), the ratio of maximal to resting flow, is reduced in these patients; a CFR below 2.0 to 2.5 defines significant impairment depending on the measurement method used.

Microvascular vasospasm is a different problem. Here the resting microvascular tone is abnormally high because of excessive smooth muscle vasoconstriction, often with an episodic or circadian pattern. Unlike epicardial vasospasm (which involves the visible large arteries), microvascular spasm occurs in vessels too small to see on angiography and does not produce the ST elevation that characterizes Prinzmetal angina. Symptoms tend to occur at rest, at night, or with low-level exertion, and acetylcholine provocation testing during catheterization can reproduce the symptoms and demonstrate the functional abnormality. Coronary flow reserve may be normal between episodes, which is why these patients are sometimes reassured incorrectly after functional testing that does not include provocation.

These two endotypes overlap in a subset of patients, but the dominant mechanism determines which treatment class is most likely to help. A beta-blocker prescribed empirically addresses demand-driven ischemia from vasodilation impairment but leaves vasospasm unaddressed. Worse, beta-blocker therapy in predominantly vasospastic disease can worsen spasm by blocking the beta-2 adrenergic receptors that mediate vasodilation and leaving alpha-adrenergic vasoconstriction unopposed. The resulting pharmacological mismatch is precisely what the CorMicA trial set out to test.

What the Evidence Shows

The CorMicA trial, published in the Lancet in 2018 by Berry and colleagues, is the first randomized controlled trial to directly test whether knowing the endotype improves treatment outcomes in patients with ischemia and no obstructive coronary artery disease (INOCA). Patients underwent invasive coronary function testing that characterized their endotype (impaired vasodilation, vasospasm, mixed, or non-cardiac), and were then randomized to receive treatment matched to that endotype result or to standard care without the functional testing information. At six months, the group whose treatment was directed by functional testing had significantly better angina symptom scores, measured by the Seattle Angina Questionnaire, than those receiving empirical care. The difference was clinically meaningful, not only statistically significant.

The CorMicA result matters because it shifts microvascular angina treatment from art to mechanism. It is not that experienced cardiologists cannot make educated guesses about endotype from history alone; it is that those guesses are wrong often enough to produce a meaningfully worse symptomatic outcome compared with knowing the answer from testing.

The CorMicA investigators published a two-year follow-up in 2020 in Heart, led by Ford and colleagues, extending the original finding. At two years, the stratified treatment group maintained better symptom control and showed improvements in quality of life measures compared with usual care. Importantly, the mechanism of improvement was specifically in patients whose treatment had been changed based on the functional testing result, not in those whose empirical treatment happened to match their endotype incidentally. The trial confirms that the value is in the diagnostic step, not only in the availability of the drugs.

Subsequent data from the Women’s Ischemia Syndrome Evaluation (WISE) study and the WISE-CVD extension provided complementary evidence on the INOCA population, with the majority of participants being women. The WISE investigators found that women with signs of ischemia and no obstructive CAD had elevated rates of microvascular dysfunction on invasive testing, adverse cardiovascular event rates substantially higher than women with completely normal studies, and symptom burdens that were undertreated relative to obstructive disease. The WISE study population is the reference cohort for understanding why dismissal of symptoms in women with normal angiograms is a clinical error.

For pharmacology, the ranolazine data deserve specific attention. The RWISE trial, published in the Journal of the American College of Cardiology in 2016 by Mehta and colleagues, randomized women with INOCA to ranolazine or placebo. While the primary endpoint of coronary flow reserve did not improve significantly, there were improvements in angina symptoms and myocardial perfusion on cardiac MRI. The trial was underpowered for the primary endpoint and the results require cautious interpretation, but they support ranolazine as a reasonable add-on option when first-line agents are insufficient. Ranolazine inhibits the late sodium current in cardiomyocytes, reducing calcium overload and myocardial oxygen demand through a mechanism distinct from conventional anti-anginals.

For statins, the benefit in microvascular angina extends beyond lipid lowering. Multiple smaller studies have documented improvements in coronary flow reserve and endothelium-dependent vasodilation with statin therapy in patients with CMD, attributed to the pleiotropic effects of statins on nitric oxide bioavailability and vascular inflammation. ACE inhibitors and ARBs show similar endothelial effects over a time course of weeks to months. These are not rapid symptom drugs; they work by restoring endothelial function progressively, which is why patients who stop them after a few weeks and report no improvement have not given the mechanism adequate time to operate.

The exercise data are specific enough to cite directly. A 2021 systematic review and meta-analysis by Mavrogeni and colleagues in Frontiers in Cardiovascular Medicine analyzed randomized controlled trials of exercise training in INOCA populations and found significant improvements in coronary flow reserve, angina frequency, and quality-of-life scores with structured exercise programs averaging 8 to 12 weeks. The European Society of Cardiology’s 2019 guidelines on chronic coronary syndromes list exercise training as a class IIa recommendation in microvascular angina, meaning it should be considered, with level B evidence.

Monitoring Treatment Response: What to Track

Microvascular angina treatment operates on a slower timescale than pharmacological interventions for obstructive coronary disease. ACE inhibitors and statins improve endothelial function over weeks to months, not hours to days. Exercise rehabilitation builds vascular adaptation over 8 to 12 weeks. A woman who starts treatment and evaluates it at two weeks has not given the mechanism time to respond. Understanding what to measure and when prevents premature discontinuation of therapies that are working but have not yet produced symptomatic improvement.

The Seattle Angina Questionnaire (SAQ) is the validated patient-reported outcome measure used in CorMicA and WISE. It covers angina frequency, physical limitation, quality of life, treatment satisfaction, and disease perception. Self-administering it before starting treatment and again at 8 and 16 weeks provides a structured comparison that captures changes the patient may otherwise attribute to general adaptation rather than treatment benefit. An improvement of 5 to 10 points on the SAQ summary score is considered clinically meaningful — below the threshold of what a patient would reliably notice as a difference in daily experience without the structured measure.

An angina diary tracking the number of weekly angina episodes, the activity level at which they occur, the number of sublingual nitroglycerin doses used per week, and the duration and intensity of each episode provides objective data independent of the patient’s overall impression of change. A woman who starts the diary when treatment begins and reviews it with her cardiologist at 12 weeks has documentation of whether episode frequency, exertion threshold, or symptom intensity has changed. Patterns that are not visible in a single clinic visit become apparent across weeks of diary data.

Exercise stress testing is appropriate at baseline and after 12 to 16 weeks of rehabilitation to document changes in peak MET capacity and the exertion threshold at which symptoms or ECG changes occur. These functional parameters directly reflect the adaptations that exercise rehabilitation is designed to produce.

Morning blood pressure trend over 14-day blocks every 3 months captures whether antihypertensive management is achieving the endothelial protection targets that also reduce microvascular resistance. A woman with CMD and morning BP consistently above 130 systolic has both a treatment gap and a mechanistic explanation for suboptimal symptom control. 3 / Early

What to Do This Week

1. If you have a microvascular angina diagnosis and are not improving on your current medications, ask specifically whether invasive coronary function testing has been done to characterize your endotype. You are looking for documentation of acetylcholine provocation to assess for vasospasm and coronary flow reserve to assess vasodilation capacity. If neither has been done, ask why, and whether a referral to a center that performs these tests is appropriate.

2. Review your current medications against the endotype framework above. If you are on a beta-blocker and your predominant symptoms are rest pain or nocturnal angina consistent with vasospasm, that conversation with your cardiologist about medication alignment is warranted. Beta-blockers in vasospastic disease can worsen the underlying problem.

3. Ask for a cardiac rehabilitation referral if you do not have one. Structured exercise training has level B, class IIa evidence in microvascular angina from the 2019 ESC guidelines and is available, consistently underused in this population, and carries a low risk profile.

4. Confirm that cardiovascular risk factor targets are being actively managed. Blood pressure at goal, LDL at target, HbA1c controlled in diabetes, and smoking cessation each address endothelial dysfunction that underlies microvascular vasodilation impairment. These interventions take months to show endothelial benefit; they are not acute symptom treatments, but they matter for the trajectory of the disease.

5. If ranolazine is not part of your current regimen and first-line anti-anginals have been inadequate, ask whether it is an appropriate addition. The RWISE trial data support it as an add-on option in women with INOCA, and its mechanism is distinct from calcium channel blockers and beta-blockers, so it adds something pharmacologically.

The Role of Psychological Comorbidity and Symptom Burden

Women with microvascular angina carry a substantial burden of anxiety, depression, and health-related quality of life impairment that is not adequately addressed by anti-anginal medication alone. The WISE study documented that women with chest pain and non-obstructive coronary disease had rates of depression and anxiety significantly above those of the general population, and that psychological comorbidity was independently associated with worse angina outcomes even after accounting for coronary functional status. This is not a statement about the symptoms being “functional” or psychosomatic. It is a statement that untreated anxiety and depression increase sympathetic tone, worsen vasospasm, and reduce pain thresholds, all of which amplify the anginal symptom burden in a patient whose coronary microvessels are already abnormal.

Treatment of microvascular angina therefore includes psychological assessment and treatment as a component of the same clinical management plan as pharmacology and exercise. Cognitive behavioral therapy has been tested in small randomized trials in INOCA populations with improvements in symptom burden and quality of life. This is not a secondary intervention or a consolation prize offered when cardiac medications have failed. It is an evidence-based component of care for a condition that is physiologically real, physiologically complex, and physiologically worsened by the psychological burden of years of dismissed symptoms.

Some women with microvascular angina will have undergone prolonged periods of symptom dismissal before reaching a clinician who performs functional testing and arrives at the correct diagnosis. The clinical encounter at which the diagnosis is finally established carries its own therapeutic weight: naming the mechanism accurately, explaining the physiology, and validating that the symptoms were never imaginary are steps that the medical literature on INOCA increasingly identifies as meaningful for patient outcomes. That is not psychiatry replacing cardiology. It is recognizing that the sequelae of inadequate prior care are part of the clinical picture that needs to be addressed.

Management of microvascular angina is not a matter of finding the right drug through trial and error. It is a process of characterizing the mechanism, matching treatment to that mechanism, and building exercise, risk factor management, and psychological support as structural components rather than optional additions. The evidence base for this approach exists. The barrier is access to functional testing and the clinical reflex to use it.